Optimizing bexarotene therapy for cutaneous T-cell lymphoma
Authors:
- Staci WardSWStaci Ward
- Narin ApisarnthanaraxNANarin Apisarnthanarax
- Joan Breuer-McHamJBJoan Breuer-McHam
- Madeleine DuvicMDMadeleine Duvic
- 1 November 2002
- journal article
- case report
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 47 (5) , 672-684
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial ResultsJournal of Clinical Oncology, 2001
- Statins as a newly recognized type of immunomodulatorNature Medicine, 2000
- HYPERLIPIDEMIAPrimary Care: Clinics in Office Practice, 2000
- EMERGING NEW THERAPIES FOR CUTANEOUS T-CELL LYMPHOMADermatologic Clinics, 2000
- Drug Treatment of Lipid DisordersNew England Journal of Medicine, 1999
- Central Hypothyroidism Associated with Retinoid X Receptor–Selective LigandsNew England Journal of Medicine, 1999
- Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patientsJournal of the American Academy of Dermatology, 1999
- Clinical Characteristics and Long-term Outcome of Patients With Generalized Patch and/or Plaque (T2) Mycosis FungoidesArchives of Dermatology, 1999
- A Randomized Trial Comparing Combination Electron-Beam Radiation and Chemotherapy with Topical Therapy in the Initial Treatment of Mycosis FungoidesNew England Journal of Medicine, 1989
- Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal PhotochemotherapyNew England Journal of Medicine, 1987